Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024 : vimarsana.com

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Parsippany , New Jersey , United States , Japan , University Of Illinois , Illinois , Tokyo , Chicago , Switzerland , Japanese , Lisa Ellen , Kenneth Candido , Raza Ahmed , Ferring Pharmaceuticals , American Society Of Interventional Pain Physicians , Kaken Pharmaceutical Co Ltd , Linkedin , Seikagaku Corporation , Seikagaku Corporation Japanese , Japanese Ministry Of Health , Lumbar Disc Herniation , American Society , Interventional Pain Physicians , Annual Meeting , Senior Director , Medical Affairs , Ferring United , Chicago Anesthesia Pain Specialists , Clinical Professor , Registrational Phase , Visual Analogue Scale , Oswestry Disability Index , Integrated Safety , After Week , Real World Treatment Pattern , Charlson Comorbidity Index , Japanese Ministry , Kaken Announce , Intradiscal Injection , Accessed March ,